PTK2 and ovarian cancer: This type of intrinsic–extrinsic multi-factorial FAK inhibition has also been observed in ovarian cancer models whereby gains in FAK expression, FAK Y397 phosphorylation and FAK activity enhance intrinsic cisplatin and taxane resistance in part through transcriptomic changes (Diaz Osterman et al., 2019; Kang et al., 2013).